

## BCAL APPOINTS EX QUEST DIAGNOSTICS EXECUTIVE DR JOHN HURRELL AS CHIEF EXECUTIVE OFFICER

- **Dr Hurrell has more than 35 years' experience in life sciences and healthcare**
- **During this time, he has developed and successfully commercialized multiple products and services as well as managing start up and early-stage companies**
- **Former executive of Quest Diagnostics & subsidiary Focus Diagnostics, where he led development & launch of more than 70 molecular diagnostic tests & gained 510(k) approvals for six products**
- **Other previous roles include Chief Commercial Officer and mentor at remote chronic disease patient management company JanaCare**
- **BCAL is developing a non-invasive laboratory blood test for the detection of breast cancer, which it has researched and invested in over the past decade as it works toward regulatory approval**

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce the appointment of experienced life science and healthcare executive Dr John Hurrell as its Chief Executive Officer (CEO).

Dr Hurrell has developed and successfully commercialized multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including successful life science companies based on university-developed technologies.

Most notably Dr Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics. Within Quest's subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and successfully gained 510(k) approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics.

Most recently, he was Chief Commercial Officer at JanaCare, a remote chronic disease patient management company with a focus on diabetes and kidney disease.

Other previous roles include President of the Asia/Pacific region and Head of International Sales for PTS Diagnostics, a diabetes and wellness company based in Indiana, USA, and Senior Executive Vice President International Business for Seegene Inc., a multinational molecular diagnostics company focusing on infectious disease, based in Seoul, South Korea.

BCAL Executive Chair Jayne Shaw commented: *"We are excited to appoint a candidate as experienced and suitably skilled as John to the Chief Executive Officer role. He has a strong track record in starting, building and improving the profitability, performance and value of life science and healthcare companies, demonstrated by his many years across international roles. We believe this will be ideal for BCAL as we continue to drive development of our technology to provide early and accurate breast cancer diagnosis to improve outcomes for patients."*

Incoming BCAL CEO Dr Hurrell said: *"BCAL's vision to develop a non-invasive blood test for the detection of breast cancer has seen extensive research and investment over the past decade and I am thrilled to be joining the company as it aims to achieve Australian and ultimately US regulatory approval for its technology, in addition to other territories. It has the potential to provide early detection of breast cancer, a disease that saw more than 2 million diagnoses in 2020, and I look forward to bringing my extensive skillset and experience in the industry to help BCAL achieve its long-term goals."*

Dr Hurrell received his Ph. D from the University of Melbourne and studied at Massachusetts General Hospital under a Fulbright Scholarship.

Dr Hurrell will commence the role on 14 February 2022. Dr Hurrell will divide his time between Australia and the USA, managing the current scientific and clinical activities based in Sydney, while at the same time preparing the company for future product launch in North America.

Dr Hurrell's remuneration is set at A\$300,000 per annum (TEC), plus a Short Term Incentive (STI) of 30% of TEC for 2022 and 50% of TEC for 2023. A Longer Term Incentive (LTI) in the form of performance rights will be put in place for the period to 30 June 2022 and then for the three years to 30 June 2025.

This ASX announcement has been approved for release by the Board of BCAL.

ENDS

### Investor & Media Enquiries

Matthew Wright  
NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 451 896 420

### About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 91% specificity and 87% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with global integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>